A combination of IMV‘s immunotherapy DPX-Survivac plus intermittent low-dose cyclophosphamide leads to sustained responses in women with heavily-treated advanced ovarian cancer, with some responses lasting more than 10 months, updated findings from a Phase 1/2 clinical trial show. “We believe these results highlight DPX-Survivac’s potential to alter the treatment landscape in advanced ovarian cancer and support its continued development,” Joanne Schindler, MD, chief medical officer at IMV, said in a press release. The results were…
You must be logged in to read/download the full post.
The post DPX-Survivac Shows Durable Responses in Advanced Ovarian Cancers, Trial Data Show appeared first on BioNewsFeeds.